News & Announcements
SNBL USA Appoints Mark T. Crane as Vice President of Business Development
November 7, 2011
SNBL USA, one of the nation's leading providers of preclinical services, is pleased to announce new executive leadership with the arrival of Mark T. Craneas Vice President of Business Development. As the new VP, Mr. Crane will have overall responsibility for the company's marketing, sales and business development efforts and will be tasked with driving the growth of SNBL USA's business model and fostering positive relationships with new and current customers.
Mr. Crane joins SNBL USA from Ricerca Biosciences where he served as Vice President of Global Sales and Marketing. He has held similar positions at Bridge Pharmaceutical, Inc. (formally GeneLogic, Inc.), Quest Pharmaceutical Services, and MDS Pharma Services. With over 25 years of industry experience, Mr. Crane is an accomplished executive with extensive expertise in management, business development, and marketing. His preclinical market knowledge and experiences from the pharmaceutical and contract research organization industries will be of significant value to SNBL USA and all its customers.
"We wanted to bring someone in to focus solely on business development and Mark is a perfect fit,” said Dr. Thomas Beck, SNBL USA president and COO. “As a seasoned industry executive, Mark's proven leadership skills will be invaluable as we plan for the coming new year and continue to refine and execute our strategy.”
About SNBL USA, Ltd.
Headquartered in Everett, WA, SNBL USA, Ltd. is a preclinical CRO that specializes in nonhuman primate (NHP) and small animal research. Study programs range from regulatory toxicology to customized study designs and disease models. Specialized programs include reproductive toxicology, safety pharmacology, immunotoxicology and carcinogenicity. SNBL USA's Laboratory Services division intelligently applies extensive experience, comprehensive scientific capabilities, and modern technology to bring outstanding support to all client research. SNBL USA SRC complements SNBL USA in providing quality NHP resources. Through a commitment to investment and excellence, SNBL USA strives to offer the biotechnology and pharmaceutical industries unparalleled quality in both science and service. For additional information call 425.407.0121 or visit www.snblusa.com.
SNBL USA is a wholly-owned subsidiary of Shin Nippon Biomedical Laboratories, Ltd. (SNBL), one of the largest CROs in Japan. Established in 1957, SNBL currently employs approximately 2,000 team members worldwide and provides full service drug development capabilities ranging from preclinical through clinical services.
Michelle Taylor, MA, 425-322-1950